ENGN Stock Analysis: Buy, Sell, or Hold?
ENGN - enGene Holdings Inc. Common Stock
$1.81
0.03 (1.69%)
▲
5d:
+6.47%
30d:
-0.55%
90d:
+10.37%
HOLD
MODERATE Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Sep 10, 2026
16d
Get Alerted When ENGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENGN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ENGN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ENGN is currently trading at $1.81, which is considered fair relative to its 30-day fair value range of $1.73 to $1.86.
Technical Outlook: Technically, ENGN is in a strong downtrend. Immediate support is located at $1.66, while resistance sits at $1.90.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.29 (+84.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENGN is in a strong downtrend. Immediate support is located at $1.66, while resistance sits at $1.90.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.29 (+84.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.73 -
$1.86
Company Quality Score
55/100
(HOLD)
Options IV Signal
22th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 22th percentile)
- NEUTRAL: Mixed technical signals (59/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 84.6% below Wall St target ($3.29)
- NEUTRAL: Bottoming setup forming (59/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$1.73 -
$1.86
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.25
(13.8%)
Support & Resistance Levels
Support Level
$1.66
Resistance Level
$1.90
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.27
Wall Street Target
$3.29
(+84.6%)
Share & Embed Analysis
Last updated: August 24, 2026 4:39 PM ET
Data refreshes hourly during market hours. Next update: 5:39 PM
Data refreshes hourly during market hours. Next update: 5:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 39 SELL |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 53 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 68 BUY |
